Skip to content
Search

Latest Stories

PHE introduces new surveillance system for early coronavirus detection

Public Health England (PHE) today announced a new surveillance system for early detection of the novel coronavirus, COVID-19.

Part of the efforts to strengthen the existing systems and to prepare for and prevent wider transmission of the virus, the new system will be implemented in intensive care units and Severe Respiratory Failure (ECMO) Centres of some NHS hospitals.


It will enable the agency to identify early evidence of spread within England.

Samples will be tested from patients with severe respiratory infections who do not meet the current case definition of COVID-19. Depending on the results, patients will be given the support they need and rapid public health actions will be taken.

Eight hospitals have so far confirmed their participation in the scheme.

“There is no change in risk for the public but taking this preparatory step now will enable us to better detect and contain the spread of the virus. The UK’s infection control procedures are world-leading, and the system we are announcing today further strengthens our response,” said Professor Yvonne Doyle, PHE’s Medical Director.

A programme of testing with a network of around 100 primary care sites across England will also complement the detection system in hospitals so that both mild and more unwell cases can be found.

PHE clarified that the new process will not apply to patients meeting the current coronavirus case definition, who will continue to be isolated and tested as appropriate, and the test results will not be affected.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less